ESMO 2025 – Datroway and Trodelvy face off in triple-negative breast
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
ESMO 2025 preview – Astra and Daiichi keep abreast of Gilead
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
